IRBM to collaborate with MSD to develop peptides against coronavirus
Builds on Research to Combat Severe Acute Respiratory Syndrome (SARS)
21st July 2020, Rome, Italy – IRBM, a global Contract Research Organization today announced a new research collaboration agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA) to identify and develop novel peptide therapeutics active against different strains of coronavirus, including SARS-CoV-2. The parties will collaborate in hit to lead optimization and preclinical drug development to rapidly advance selected candidates towards the clinic.
WHYUS
We offer a unique blend of broad scientific expertise, global pharma heritage, and unprecedented success in bringing drug discovery projects from conception to the clinic. With a passionate, interdisciplinary and accomplished team, and capabilities ranging from target validation to clinical candidate nomination, we bring great science to your project.
NewsEvents
Identification of Potent and Long-Acting Single-Chain Peptide Mimetics of Human Relaxin-2 for Cardiovascular Diseases
Our integrated drug discovery efforts on the Relaxin-2 peptide hormone, in collaboration with our collaborators at global life sciences company…
On July 7 University and Research Minister Gaetano Manfredi visited IRBM
On June 18 Health Minister Roberto Speranza, together with Nicola Magrini Director General of AIFA, visited IRBM
Covid, a young international team: that’s how Pomezia works on the vaccine
In an 80,000 m2 site 20 miles from Rome, young researchers from around the world work day and night making…
IRBMPHOTOS
